Oral Spermidine Targets Brown Fat and Skeletal Muscle to Mitigate Diet-Induced Obesity and Metabolic Disorders.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro mechanistic study
PubMed 34363644 · doi:10.1002/mnfr.202100315
What was done
Mice fed a high-fat diet (HFD) received oral spermidine to assess effects on weight gain, insulin resistance, hepatic steatosis, and white adipose tissue inflammation. The researchers also performed in vitro and tissue-level mechanistic assays in mice, cultured neurocytes, brown adipocytes, and myotubes to evaluate hypothalamic tyrosine hydroxylase expression, norepinephrine production, CREB activation, and UCP-1 and PGC-1α expression.
What was found
The abstract reports directional findings without numerical values, effect sizes, or confidence intervals. Oral spermidine reduced weight gain, insulin resistance, hepatic steatosis, and white adipose tissue inflammation in HFD-fed mice. Mechanistically, spermidine induced UCP-1 and activated CREB in brown adipose tissue and skeletal muscle, upregulated hypothalamic tyrosine hydroxylase, increased neurocyte norepinephrine production, and directly stimulated UCP-1 and PGC-1α expression in brown adipocytes and myotubes.
Why it matters
This study identifies central (hypothalamic) and direct peripheral mechanisms through which oral spermidine promotes brown fat activation and muscle adaptation to counteract metabolic dysfunction in mice.
Limits
The study is entirely preclinical, relying on rodent models and cell cultures; findings cannot be directly applied to human clinical management. The abstract does not disclose sample sizes, treatment duration, specific spermidine dosages, or quantitative effect sizes.
Cited by
- supports Administering spermidine to mice fed a high-fat diet reduces weight gain.